Veterinary Drug

Veterinary Drug Market Outlook

The global veterinary drug market is projected to reach approximately USD 45.3 billion by 2025, growing at a compound annual growth rate (CAGR) of around 6.2% from 2025 to 2035. This growth trajectory can be attributed to several key factors, including the increasing prevalence of zoonotic diseases, rising pet ownership, and heightened consumer awareness regarding animal health and welfare. Moreover, advancements in veterinary medicine and the growing demand for high-quality veterinary pharmaceuticals are further propelling market growth. The expansion of the livestock sector and the growing demand for safe and healthy animal protein are also critical contributors to the market's upward movement. Furthermore, the rising trend of pet humanization is leading to increased spending on companion animals, thereby boosting the demand for a wide array of veterinary drugs.

Growth Factor of the Market

One of the primary growth factors driving the veterinary drug market is the increased focus on animal health and welfare, particularly in response to the rising incidence of zoonotic diseases that can transfer from animals to humans. As global trade and travel expand, the risk of disease transmission becomes more pronounced, prompting governments and health organizations to invest heavily in veterinary drug development and regulation. Additionally, the growing population of pet owners who view their pets as family members is fostering a culture of preventative care, leading to increased demand for veterinary pharmaceuticals, including vaccines and health supplements. Furthermore, advancements in biotechnology and pharmacology are yielding innovative treatments that enhance the efficacy and safety of veterinary drugs, a trend that is particularly appealing to both veterinary professionals and pet owners alike. The burgeoning livestock sector, especially in developing economies, is also a significant contributor to market expansion as producers aim to enhance productivity and ensure food safety. Lastly, the ongoing integration of digital health technology in veterinary practices is facilitating better patient monitoring and treatment, thereby creating new avenues for veterinary drug sales.

Key Highlights of the Market

• The market is projected to reach USD 45.3 billion by 2025, with a CAGR of 6.2% from 2025 to 2035.
• Growing pet ownership and the trend of pet humanization are significantly influencing market dynamics.
• The livestock industry is increasingly adopting veterinary drugs to ensure healthy and productive animals.
• Advancements in biotechnology are leading to the development of innovative and safer veterinary pharmaceuticals.
• The rise of e-commerce and online pharmacies is transforming the distribution channels for veterinary drugs.

By Product Type

Antibiotics:

Antibiotics are vital in the veterinary drug market, representing a significant portion of drug sales aimed at treating bacterial infections in both livestock and companion animals. The rising incidence of infections among animals, compounded by the increasing adoption of antibiotic therapies, underscores the importance of this segment. Antibiotics not only help in treating acute infections but are also used in prophylactic measures to prevent potential outbreaks, especially in livestock. This segment has seen a strong push for responsible use, with regulations and guidelines being established to mitigate the risks of antibiotic resistance. The ongoing research and development efforts to create novel antibiotics that can target specific pathogens further promote the growth of this segment, as veterinary professionals seek effective solutions for animal health challenges.

Vaccines:

Vaccines play a crucial role in preventing infectious diseases in animals, making them one of the fastest-growing segments in the veterinary drug market. The increasing awareness regarding disease prevention among pet owners and livestock producers has significantly boosted the demand for vaccines. This surge is further supported by advancements in vaccine technology, including the development of recombinant and DNA vaccines that offer improved efficacy. Additionally, the global trend towards preventive healthcare is prompting greater investment in vaccine research and development, leading to the introduction of innovative products tailored for various animal species. The rising prevalence of zoonotic diseases and the need for immunization against emerging pathogens are also important factors driving the expansion of this segment.

Parasiticides:

Parasiticides, which are used to control internal and external parasites in animals, represent a significant sector within the veterinary drug market. The growing concern over parasite-related diseases and their impact on animal health has led to an increase in the demand for effective parasiticide solutions. As livestock and pet owners become more aware of the health risks associated with parasitic infections, the adoption of these drugs has surged. Advances in formulation technologies have also enhanced the effectiveness and safety profiles of parasiticides, further driving their acceptance. The persistent threat of parasitic infestations, especially in regions with warmer climates, necessitates ongoing development and promotion of innovative treatments, making this segment crucial for sustaining animal health and productivity.

Anti-inflammatory Drugs:

Anti-inflammatory drugs are essential in managing pain and inflammation in animals, a growing concern that has gained heightened attention from veterinarians and pet owners alike. These drugs are commonly used in both companion animals and livestock to alleviate discomfort from various conditions, such as arthritis, surgical recovery, and other inflammatory diseases. The increasing recognition of animal pain management as a vital aspect of veterinary care is driving the demand for these drugs. With the advancements in pharmaceutical formulations and the availability of newer compounds, veterinarians are now better equipped to provide effective pain relief. Additionally, the rise in companion animal adoption and the growing emphasis on quality of life for pets are contributing to the robust growth of this segment.

Others:

The "Others" category in the veterinary drug market encompasses a diverse range of pharmaceuticals that do not fit into the standard classifications of antibiotics, vaccines, parasiticides, or anti-inflammatory drugs. This category includes a variety of therapeutic agents, such as hormones, anesthetics, and metabolic modifiers, which are essential for treating specific health conditions in animals. The demand for these products is driven by the ongoing research into animal health and the development of targeted therapies that address unique health challenges. With increasing attention on specialized veterinary care, this segment is expected to see steady growth, particularly as veterinarians seek comprehensive treatment options tailored to individual animal needs.

By Application

Livestock:

The livestock application segment is a substantial portion of the veterinary drug market, driven by the need for disease prevention and management in agricultural animals. As the global demand for animal protein continues to rise, livestock producers are increasingly investing in veterinary drugs to ensure the health and productivity of their herds. This application encompasses various species, including cattle, poultry, and swine, each facing unique health challenges. The focus on biosecurity measures and the prevention of disease outbreaks is significant, leading to higher adoption rates of vaccines and therapeutic drugs. Additionally, the growing awareness of livestock welfare and the importance of responsible antibiotic use are shaping the practices within this segment, further driving market growth.

Companion Animals:

Companion animals represent one of the most dynamic segments in the veterinary drug market, fueled by the increasing trend of pet ownership and the humanization of pets. Pet owners are becoming more informed about animal health and are willing to invest in veterinary care, including preventive and therapeutic medications. This segment has witnessed a notable rise in the use of veterinary drugs, particularly for chronic conditions such as obesity, diabetes, and dermatological disorders. The ongoing development of specialized drugs and treatments aimed at enhancing the quality of life for pets is further stimulating market growth. Additionally, the demand for preventive care, including vaccinations and regular health check-ups, remains strong, positioning the companion animal segment as a key driver of the overall veterinary drug market.

By Distribution Channel

Veterinary Hospitals:

Veterinary hospitals serve as a primary distribution channel for veterinary drugs, playing a pivotal role in delivering health care to animals. These facilities offer a wide range of services, including examinations, diagnostics, and treatments, making them essential for the administration of various veterinary pharmaceuticals. The trend towards more sophisticated veterinary hospitals equipped with advanced diagnostic and treatment technologies is driving the demand for a comprehensive inventory of veterinary drugs. Furthermore, the increasing number of specialty animal hospitals focusing on specific health conditions is contributing to the growth of this distribution channel, as they require a wider array of pharmaceuticals to adequately address the needs of their patients.

Veterinary Clinics:

Veterinary clinics are another crucial distribution channel in the veterinary drug market, often serving as the first point of contact for pet owners seeking medical attention for their animals. These clinics typically offer routine services such as vaccinations and wellness examinations, driving the demand for various preventive medications. The convenience and accessibility of veterinary clinics are significant factors in their popularity, further bolstered by the rising number of clinics catering to the growing pet population. Additionally, the increasing focus on preventive health care and the management of chronic diseases among pets is leading to an expansion of the range of veterinary drugs available in these clinics, thereby enhancing their role in the overall market.

Pharmacies:

Pharmacies represent a growing distribution channel for veterinary drugs, particularly as more states and countries allow licensed pharmacists to provide veterinary medications. This trend is being driven by consumer demand for convenience and accessibility to veterinary products, especially for chronic conditions requiring ongoing therapy. Pharmacies are increasingly stocking a variety of over-the-counter veterinary drugs, such as anti-parasitic medications and nutraceuticals, catering to pet owners who seek easy access to these products. Furthermore, the collaboration between veterinarians and pharmacists is enhancing the quality of care provided, making pharmacies a beneficial channel in the veterinary drug market.

Online Pharmacies:

The rise of e-commerce has significantly transformed the distribution landscape of the veterinary drug market, with online pharmacies becoming an increasingly popular channel for pet owners. The convenience of browsing and purchasing medications from the comfort of home is a significant driving factor, particularly for those in remote areas or with limited access to veterinary care. Online pharmacies offer a broad selection of veterinary drugs, often at competitive prices, which appeals to cost-conscious consumers. This channel has also benefited from advancements in telemedicine, allowing pet owners to consult with veterinarians and receive prescriptions digitally. As the trend towards online shopping continues to grow, the veterinary drug market is likely to see increased participation from this distribution channel.

By Ingredient Type

Antibiotics:

Within the ingredient type segment, antibiotics are essential for treating a wide range of bacterial infections in both livestock and companion animals. The growing awareness regarding the health risks posed by untreated infections is driving the demand for antibiotic treatments in veterinary care. Responsible antibiotic use is becoming a focal point in veterinary medicine, leading to the development of new formulations that minimize resistance risks while maintaining efficacy. Furthermore, regulatory bodies are increasingly promoting the judicious use of antibiotics, which entails a more selective approach to their application in veterinary practice. Ongoing research into novel antibiotics capable of targeting specific bacterial strains is expected to support continued growth in this ingredient type.

Vaccines:

The vaccine ingredient segment is crucial for ensuring the health of animals by providing immunity against infectious diseases. The market for veterinary vaccines has expanded due to the rising awareness among pet owners and livestock producers about the importance of vaccination in preventing outbreaks. Innovative vaccine technologies, such as recombinant and inactivated vaccines, are enhancing efficacy and safety profiles, contributing to increased adoption rates. Additionally, the introduction of combination vaccines that offer protection against multiple diseases in a single administration is further driving this segment's growth. As the focus on preventive healthcare continues to gain momentum, the demand for vaccines is poised for sustained expansion.

Parasiticides:

Parasiticides are vital ingredients in the veterinary drug market, designed to control parasites that affect the health of both livestock and companion animals. The persistent threat of parasitic infestations drives demand for effective parasiticides, and ongoing advancements in formulation and delivery methods are enhancing their effectiveness. The importance of preventing parasite transmission in livestock, particularly in food safety and production efficiency, underscores the growth potential of this ingredient type. Moreover, the rising awareness of the health implications of parasitic infections in pets is prompting pet owners to seek out effective treatments, thereby fueling the growth of the parasiticide market. The continuous development of new and improved parasiticide formulations will further bolster this segment's importance within the veterinary drug landscape.

Anti-inflammatory Drugs:

Anti-inflammatory drugs are critical components of the veterinary drug market, providing essential treatment options for managing pain and inflammation in animals. The increasing recognition of the importance of pain management in veterinary care is driving the demand for these drugs. As veterinarians become more attuned to the necessity of alleviating discomfort in animals, the usage of anti-inflammatory medications has surged. Advances in the development of safer, more effective anti-inflammatory drugs are also enhancing their appeal among veterinary practitioners. As the trend towards enhancing animal welfare continues to grow, the demand for anti-inflammatory drugs is expected to remain strong across various animal species, further solidifying their role as a key ingredient type in the veterinary drug market.

By Region

The veterinary drug market exhibits significant regional variations, heavily influenced by factors such as veterinary care infrastructure, consumer awareness, and animal health regulations. North America holds a substantial share of the market, driven by high pet ownership rates and advanced veterinary healthcare practices. The region is projected to grow at a CAGR of 6.0% during the forecast period, fueled by the increasing demand for innovative veterinary pharmaceuticals and preventive healthcare solutions. Europe follows closely, benefiting from a well-established veterinary care system and a growing emphasis on animal welfare. The European market is also responding to the rising trend of pet humanization, which is leading to increased spending on veterinary care and medications.

In contrast, the Asia Pacific region shows immense growth potential, estimated to grow at a CAGR of 7.5% from 2025 to 2035, attributed to rising disposable incomes, a growing population of pet owners, and expanding livestock operations. Countries like India and China are experiencing a rapid increase in both pet adoption and livestock farming, thereby significantly contributing to the demand for veterinary drugs. Latin America and the Middle East & Africa are also witnessing growth due to evolving veterinary care practices and increasing awareness of animal health. However, these regions are currently at a different stage in market development compared to North America and Europe, which reflects in their growth rates and market dynamics.

Opportunities

The veterinary drug market presents numerous opportunities driven by ongoing advancements in technology and increasing investment in research and development. One notable opportunity lies in the growing focus on biotechnology and genomics in veterinary medicine. The utilization of biopharmaceuticals, including monoclonal antibodies and gene therapies, is becoming increasingly prominent in treating animal diseases. This trend presents an opportunity for companies to innovate and develop cutting-edge products that address complex health challenges faced by animals. Additionally, the rising trend of personalized veterinary medicine, which tailors treatments to individual animals based on genetic and health profiles, is expected to create further avenues for growth and differentiation in the market. The integration of digital health technologies, such as telemedicine and mobile applications, into veterinary practices also opens new channels for delivering care and monitoring animal health, driving demand for veterinary drugs.

Another significant opportunity lies in expanding the market for preventive healthcare solutions. As pet owners and livestock producers increasingly prioritize disease prevention, demand for vaccines and preventative medications is expected to rise. This shift towards proactive health management creates a favorable environment for pharmaceutical companies to introduce new preventive products. Furthermore, the growth of e-commerce and online pharmacies presents an opportunity for companies to reach a broader customer base and capitalize on the convenience-driven purchasing behavior of consumers. By leveraging digital platforms for marketing and distribution, companies can enhance accessibility to veterinary drugs, ultimately promoting better animal health outcomes and driving sales growth in this dynamic market.

Threats

Despite the promising growth prospects, the veterinary drug market faces several threats that could impede its progress. One of the primary concerns is the increasing prevalence of antibiotic resistance, which poses a significant challenge for veterinary medicine. As the use of antibiotics continues to rise, particularly in livestock, the risk of resistant bacterial strains emerging becomes more pronounced. This challenge not only has implications for animal health but also raises public health concerns, leading to stricter regulations and guidelines governing antibiotic use in veterinary settings. Companies operating in this space must remain vigilant and proactive in addressing this issue, as failure to do so could restrict their product offerings and market access.

Another prominent threat is the regulatory landscape surrounding veterinary pharmaceuticals. The development and approval process for veterinary drugs can be lengthy and complex, with varying requirements across regions. Stringent regulations may pose barriers to entry for new market entrants and slow down the introduction of innovative products. Additionally, any adverse events associated with veterinary drugs can lead to recalls or increased scrutiny from regulatory bodies, further complicating the market landscape. Moreover, economic factors such as fluctuations in commodity prices and changing consumer preferences can impact the demand for veterinary drugs, particularly in the livestock sector. Companies need to navigate these challenges strategically to maintain their competitive edge and ensure sustainable growth in the veterinary drug market.

Competitor Outlook

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Ceva Santé Animale
• Virbac
• Vetoquinol S.A.
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals PLC
• Aratana Therapeutics
• Heska Corporation
• Noble Animal Health
• Vetiquinol
• Merial (now part of Boehringer Ingelheim)
• Animal Health International, Inc.

The competitive landscape of the veterinary drug market is characterized by the presence of several key players, each offering a diverse portfolio of products aimed at improving animal health. Major pharmaceutical companies such as Zoetis, Merck Animal Health, and Boehringer Ingelheim lead the market, leveraging their extensive research capabilities and established distribution networks to maintain a competitive edge. These companies focus on innovation, investing heavily in research and development to introduce advanced veterinary pharmaceuticals that address the evolving needs of veterinarians and pet owners. Additionally, they engage in strategic partnerships and collaborations to enhance their product offerings and expand their market reach. The emphasis on animal welfare and the growing demand for preventive healthcare solutions are driving these companies to prioritize the development of vaccines and other preventive medications.

Elanco Animal Health is another prominent player in the market, renowned for its commitment to animal health and well-being. The company focuses on a diverse range of veterinary pharmaceuticals, including antibiotics, vaccines, and parasiticides, catering to both livestock and companion animal sectors. Elanco's strong market presence is bolstered by its strategic acquisitions and collaborations, which facilitate the development of innovative solutions tailored to meet the specific health challenges faced by animals. The company's dedication to research and development, along with its robust distribution network, positions it as a key contributor to the veterinary drug market.

Smaller companies, such as Vetoquinol and Ceva Santé Animale, also play a vital role in the competitive landscape, specializing in niche areas of veterinary medicine. These companies often focus on specific therapeutic categories or regions, allowing them to develop expertise and build strong relationships with veterinarians and animal health professionals. Additionally, their agility and willingness to adapt to market changes enable them to introduce innovative products and services that resonate with the needs of their customers. The ongoing evolution of the veterinary drug market presents both challenges and opportunities for these companies, driving them to continuously enhance their offerings and strengthen their market positions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Virbac
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Vetiquinol
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Zoetis Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Vetoquinol S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Heska Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck Animal Health
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Noble Animal Health
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Aratana Therapeutics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Elanco Animal Health
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Ceva Santé Animale
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Dechra Pharmaceuticals PLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Phibro Animal Health Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Animal Health International, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Merial (now part of Boehringer Ingelheim)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Veterinary Drug Market, By Application
    • 6.1.1 Livestock
    • 6.1.2 Companion Animals
  • 6.2 Veterinary Drug Market, By Product Type
    • 6.2.1 Antibiotics
    • 6.2.2 Vaccines
    • 6.2.3 Parasiticides
    • 6.2.4 Anti-inflammatory Drugs
    • 6.2.5 Others
  • 6.3 Veterinary Drug Market, By Ingredient Type
    • 6.3.1 Antibiotics
    • 6.3.2 Vaccines
    • 6.3.3 Parasiticides
    • 6.3.4 Anti-inflammatory Drugs
  • 6.4 Veterinary Drug Market, By Distribution Channel
    • 6.4.1 Veterinary Hospitals
    • 6.4.2 Veterinary Clinics
    • 6.4.3 Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Veterinary Drug Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Veterinary Drug market is categorized based on

By Product Type

• Antibiotics
• Vaccines
• Parasiticides
• Anti-inflammatory Drugs
• Others

By Application

• Livestock
• Companion Animals

By Distribution Channel

• Veterinary Hospitals
• Veterinary Clinics
• Pharmacies
• Online Pharmacies

By Ingredient Type

• Antibiotics
• Vaccines
• Parasiticides
• Anti-inflammatory Drugs

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Zoetis Inc.
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Ceva Santé Animale
• Virbac
• Vetoquinol S.A.
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals PLC
• Aratana Therapeutics
• Heska Corporation
• Noble Animal Health
• Vetiquinol
• Merial (now part of Boehringer Ingelheim)
• Animal Health International, Inc.